Beta-Blocker Therapy Does Not Alter the Rate of Aortic Root Dilation in Pediatric Patients with Marfan Syndrome - 12/08/11
, Brian Feingold, MD 
, Beth F. Printz, MD, PhD, Sang C. Park, MD, Dionne Graham, PhD, Charles S. Kleinman, MD, C. Becket Mahnke, MD, Donna M. Timchak, MD, William H. Neches, MD, Welton M. Gersony, MDReprint requests: Elif Seda Selamet Tierney, MD, Children’s Hospital Boston, Department of Cardiology, 300 Longwood Avenue, Boston, MA 02155.Résumé |
Objective |
To test the hypothesis that chronic beta-blocker therapy in pediatric patients with Marfan syndrome alters the rate of aortic root dilation. Beta-blockade has been advocated as preventive therapy for Marfan syndrome based on reports indicating a decreased rate of aortic root dilation in treated patients.
Study design |
Patients with Marfan syndrome (n = 63) followed at Children’s Hospital of Pittsburgh or Children’s Hospital of New York-Presbyterian who had ≥18 months of echocardiographic follow-up were studied. All clinical data and 213 serial echocardiograms were reviewed, and aortic root dimensions were measured. Patients were divided into 2 groups for comparison: untreated (n = 34) and treated (n = 29).
Results |
At study entry, the 2 study groups were comparable in terms of age, sex, body surface area (BSA), aortic root measurements, heart rate, and corresponding z scores. Follow-up duration in each group was similar. At last follow-up, heart rates and heart rate z scores were lower in the treated group. Rates of change of aortic root measurements (P = .52) and the corresponding z scores were not statistically different between the 2 group at the study’s end.
Conclusions |
This study suggests that that beta-blocker therapy does not significantly alter the rate of aortic root dilation in children with Marfan syndrome. Based on these data, the recommendation of lifetime beta-blocker therapy instituted during childhood should be reassessed.
Le texte complet de cet article est disponible en PDF.Abbreviations : BSA, CHONY, CHP
Plan
| The authors have no conflicts of interest to disclose. |
Vol 150 - N° 1
P. 77-82 - janvier 2007 Retour au numéro
Article précédent
- Takayasu Arteritis in Children: Preliminary Experience with Cyclophosphamide Induction and Corticosteroids Followed by Methotrexate
- Seza Ozen, Ali Duzova, Aysin Bakkaloglu, Yelda Bilginer, Barbaros E. Cil, Metin Demircin, Jean Claude Davin, Mehmet Bakkaloğlu
- Bone Mineral Density in Children and Adolescents with Neurofibromatosis Type 1
- David A. Stevenson, Laurie J. Moyer-Mileur, Mary Murray, Hillarie Slater, Xiaoming Sheng, John C. Carey, Bukhosi Dube, David H. Viskochil
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?